Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 5Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Glioma 20Glioblastoma 15Brain Neoplasms 11Neuroblastoma 4Neoplasms 4Astrocytoma 4Sarcoma 3Prostatic Neoplasms 2Neurofibromatosis 1 2Neoplastic Cells, Circulating 2Meningioma 2Lung Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Wilms Tumor 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Radiation Injuries 1Polycystic Kidney, Autosomal Recessive 1Pituitary Neoplasms 1Pheochromocytoma 1Parkinsonian Disorders 1Paraganglioma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neurofibromatosis-Noonan syndrome 1Neurofibromatoses 1Neoplasms, Germ Cell and Embryonal 1

Interventions

Cyclophosphamide 10Temozolomide 8X-Rays 7Specimen Handling 7Irinotecan 7Phantoms, Imaging 6Magnetic Resonance Spectroscopy 6Filgrastim 6Carboplatin 5Biopsy 5fludarabine 4Nuclear Medicine Department, Hospital 4olaparib 3fludarabine phosphate 3etoposide phosphate 3dinutuximab 3Zoledronic Acid 3Oxaliplatin 3Nivolumab 3Ifosfamide 3Granulocyte Colony-Stimulating Factor 3Gemcitabine 3Etoposide 3Docetaxel 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2lorukafusp alfa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × Blood Specimen Collection × CNS × Clear all
NCT03860207 2023-09-13

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Y-mAbs Therapeutics

Phase 1/2 Terminated
12 enrolled 15 charts
CNSSarcoma

Neuroblastoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡